With its appropriate size of 80-200 nm, Cytonacx is a non-viral nanoparticle showing high transfection efficiency and high cell and tissue specificity, while not involving viral genomes. This enveloped therapeutic bionanoparticle will be able to bind to cell-surface receptors and engage in target cell membrane fusion. By delivering molecular therapeutics, such as plasmid DNA, siRNA, peptides without disturbing cellular normal life events, Cytonacx is playing a powerful role in molecular therapy. With PEGylation, Cytonacx exhibits its natural properties of risk-free and long-lasting gene transduction, overcoming limitations of viral vectors and synthetic liposomes in gene therapy. Now Cytonacx comes as particular types of bionanoparticles carrying cures for human diseases such as cancer or AIDS.
Relatively larger gaps between adjacent endothelial cells in tumor neovasculature allows Cytonacx for passive targeting to the tumor site, while poor lymphatic drainage leads to relatively high retention of Cytonacx therapeutics within the tumor mass. Cytonacx carrying CDC6 shRNA-producing plasmid DNA would be a promising candidate for molecular therapy of cancer. Cdc6 depletion by using CDC6 siRNA has shown to induce apoptosis in human hepatocarcinoma cell lines and cervical carcinoma HeLa cells. Lentivirual vector producing CDC6 shRNA has induced cell death upon Cdc6 knockdown. Moreover, infection of human breast carcinoma cells with the virus induces proliferative senescence.
At present time, the product of Cytonacx/CDC6 shRNA is in a form of PEI-PDNA nanoparticles enveloped with purified VSV/G protein. Protected by PRGylation, these bionanoparticles are processed via ultrafiltration, concentration, and dialysis. The tested doses of Cytonacx are 80-160 mg DNA per 500 ml of purified injection. Cytonacx can be orally administered, 160 mg DNA per week, three-week treatment is a treatment period. Cytonacx can also be injected directly into cancerous foci, inject 80-160 mg DNA each time, once a week, three-week injection will be a treatment period. It can also be intra-vascular administered for those patients with cancer spreading or metastases. Use one injection diluted with 50 ml of 0.9% NaCl for intravenous administration, once a week, 3 injections for a treatment period.
TransEff is a kind of enveloped nanoparticle. Used as gene delivery vehicle, TransEff brings plasmid DNA, siRNA, or protein peptides into target cells in high efficiency with low or non-toxic to the cell in vitro or in vivo. The nanoparticles carry the plasmid DNA entering cells, transfer to nucleus and release the plasmid DNA for associating with chromosomal genome. Or, the nanoparticles deliver siRNA inside cytosolic parts of the cell for RNAi effect. TransEff can introduces as much as 10-35 pg?0.1-0.35X10-6 mg?DNA, siRNA or other type of payloads into a single cells by just incubating the nanoparticles with tissue cultures. Prepacked with a plasmid carrying a puromycin-resistant gene makes it possible for you to find interesting transduced cell clones in less than 40-hour selection.